{"disease":{"id":"acute-myeloid-leukemia-relapsed-adult","name":"acute myeloid leukemia relapsed adult"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03985007","title":"CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02957032","title":"A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Philogen S.p.A.","has_results":false},{"nct_id":"NCT05029141","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03063203","title":"Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04347616","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03245424","title":"Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}